BACKGROUND: Human papillomavirus (HPV) causes anal intraepithelial neoplasia (AIN) in HIV-seropositive men. The detection of HPV genotypes in anal biopsies and swabs was compared. METHODS: HPV DNA was detected in anal swabs and biopsies obtained concurrently from 154 HIV-seropositive men [31 without AIN, 60 low-grade AIN (AIN-1), 62 high-grade AIN (AIN-2,3), and 1 indeterminate AIN] under or eligible to highly active antiretroviral therapy. RESULTS: HPV DNA was detected in 24.2% of normal biopsies compared with 93.5% with AIN-2,3 (P < 0.001) and 88.3% with AIN-1 (P < 0.001). The proportion of biopsies containing multiple genotypes was greater in AIN-1 (n = 21, 35.0%; P = 0.002) and AIN-2,3 (n = 38, 58%; P < 0.001) than in normal biopsies (n = 2, 6.5%). The most frequent genotypes in order of frequency were in AIN-2,3 biopsies HPV-16, 18, 58, and 45 and were in AIN-1 biopsies HPV-6, 11, 16, and 39. Controlling for age, CD4 count, and smoking, the presence of high-risk HPV DNA in biopsies [odds ratio (OR) = 50.8, 95% confidence interval (CI): 13.0 to 199.5] but not in swabs (OR = 2.0, 95% CI: 0.6 to 7.0) was associated with AIN-2,3. CONCLUSIONS: AIN-2,3 was associated with high-risk HPV infection detected in biopsies but not in swabs in men under or starting highly active antiretroviral therapy, possibly due to the presence of HPV foci outside of the neoplastic lesion.
BACKGROUND:Human papillomavirus (HPV) causes anal intraepithelial neoplasia (AIN) in HIV-seropositivemen. The detection of HPV genotypes in anal biopsies and swabs was compared. METHODS:HPV DNA was detected in anal swabs and biopsies obtained concurrently from 154 HIV-seropositivemen [31 without AIN, 60 low-grade AIN (AIN-1), 62 high-grade AIN (AIN-2,3), and 1 indeterminate AIN] under or eligible to highly active antiretroviral therapy. RESULTS:HPV DNA was detected in 24.2% of normal biopsies compared with 93.5% with AIN-2,3 (P < 0.001) and 88.3% with AIN-1 (P < 0.001). The proportion of biopsies containing multiple genotypes was greater in AIN-1 (n = 21, 35.0%; P = 0.002) and AIN-2,3 (n = 38, 58%; P < 0.001) than in normal biopsies (n = 2, 6.5%). The most frequent genotypes in order of frequency were in AIN-2,3 biopsies HPV-16, 18, 58, and 45 and were in AIN-1 biopsies HPV-6, 11, 16, and 39. Controlling for age, CD4 count, and smoking, the presence of high-risk HPV DNA in biopsies [odds ratio (OR) = 50.8, 95% confidence interval (CI): 13.0 to 199.5] but not in swabs (OR = 2.0, 95% CI: 0.6 to 7.0) was associated with AIN-2,3. CONCLUSIONS: AIN-2,3 was associated with high-risk HPV infection detected in biopsies but not in swabs in men under or starting highly active antiretroviral therapy, possibly due to the presence of HPV foci outside of the neoplastic lesion.
Authors: Amy S Baranoski; Richa Tandon; Janice Weinberg; Faye F Huang; Elizabeth A Stier Journal: Am J Obstet Gynecol Date: 2012-03-30 Impact factor: 8.661
Authors: Roswell Quinn; Javier Salvatierra; Vicky Solari; Martha Calderon; Thanh G N Ton; Joseph R Zunt Journal: AIDS Res Hum Retroviruses Date: 2012-06-01 Impact factor: 2.205
Authors: Philip E Castle; Stephen Follansbee; Sylvia Borgonovo; Diane Tokugawa; Lauren M Schwartz; Thomas S Lorey; Brandon LaMere; Julia C Gage; Barbara Fetterman; Teresa M Darragh; Ana Cecilia Rodriguez; Nicolas Wentzensen Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-11-15 Impact factor: 4.254
Authors: Montserrat Torres; Cristina González; Jorge del Romero; Pompeyo Viciana; Antonio Ocampo; Patricia Rodríguez-Fortúnez; Mar Masiá; José Ramón Blanco; Joaquín Portilla; Carmen Rodríguez; Beatriz Hernández-Novoa; Julia del Amo; Marta Ortiz Journal: J Clin Microbiol Date: 2013-08-21 Impact factor: 5.948
Authors: Saverio G Parisi; Mario Cruciani; Renzo Scaggiante; Caterina Boldrin; Samantha Andreis; Federico Dal Bello; Silvana Pagni; Andrea Barelli; Andrea Sattin; Carlo Mengoli; Giorgio Palù Journal: BMC Infect Dis Date: 2011-05-25 Impact factor: 3.090
Authors: Alyssa M Cornall; Jennifer M Roberts; Monica Molano; Dorothy A Machalek; Samuel Phillips; Richard J Hillman; Andrew E Grulich; Fengyi Jin; I Mary Poynten; David J Templeton; Suzanne M Garland; Sepehr N Tabrizi Journal: BMJ Open Date: 2015-08-26 Impact factor: 2.692